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i(17q) G- banding (left) - Courtesy Jean-Luc Lai (top) and Diane 
H. Norback, Eric B. Johnson, and Sara Morrison-Delap,  UW 
Cytogenetic Services (middle and bottom); and R- banding 
(right) - top: Editor, bottom: Courtesy Jacques Boyer. 
Note: An isochromosome 17 results in a loss of the 
short arm (17p) and duplication of the long arm (17q) 
leading to a single copy of 17p and three copies of 17q. 
An i(17q), usually observed in a complex karyotype, 
has been reported in solid tumors and in various types 
of hematological diseases: acute and chronic myeloid 
leukemias, acute lymphoid leukemiasand chronic 
lymphoid leukemias, and Hodgkin and non-Hodgkin 
lymphomas. 
In chronic myeloid leukemia, i(17q) is a frequent ad 
well known secondary anomaly, either solely in 10% of 
cases, or with other additional anomalies, in at lest 
another 10% of cases, in particular with +8. 
Clinics and pathology 
Disease 
Myeloproliferative / myelodysplastic diseases 
(MPD/MDS). 
Phenotype/cell stem origin 
Previous studies on isolated i(17q) have suggested this 
aberration was associated with chronic myeloid 
abnormalities with a high rate of progression to ANLL; 
a new clinico-pathological entity in which i(17q) is the 
sole abnormality has been reported in a mixed 
myeloproliferative disorder / myelodysplastic 
syndrome with an aggressive course; if teen patients 
were included in this study classified as chronic 
myeloid malignancy at initial presentation: these 
features were not confirmed after a negative molecular 
BCR-ABL analysis in all cases studied (eleven 
patients). 
Etiology 
i(17q) as sole cytogenetic aberration represents only
1% of cases in myeloid malignancies. 
Cytology 
A severe hyposegmentation of neutrophil nuclei 
(pseudo-Pelger Huet neutrophils (PHH)) and a 
prominence of the monocyte/macrophage lineage has 
been noted; other studies have identified an associati n 
between hyposegmented neutrophils and loss of 17p  
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(called 17p- syndrome), always included in complex 
karyotypes; the i(17q) appeared to be a part of the 
malignant clone as demonstrated in cases available for 
a FISH analysis: all myeloid cell lines observed 
contained the abnormal i(17q), whereas none of the 
lymphocytes were affected. 
Prognosis 
By standard Kaplan-Meier analysis, the median 
survival was 2.5 years (range 0.85-5.25 years). 
Genes involved and proteins 
Note 
The underlying molecular defect that produces the 
isolated i(17q) is unknown: breakage of the proximal p 
arm (17p11.2) with rejoining of both centromere-
containing chromatids and subsequent inactivation of 
one centromere; breakpoints could involve important 
genetic material whose disruption could result in 
oncogene or tumor suppression gene deregulation. 
In understanding the specific i(17q) phenotype, loss f 
genes localized on 17p were suggested as p53 
(17p13.1); a direct correlation between p53 loss and
PHH neutrophils was found in a series of MDS and 
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